White B G
Prog Clin Biol Res. 1985;197:83-93.
By collaborating with the pharmaceutical industry in key areas of drug development, the ADD Program of the Epilepsy Branch, National Institute of Neurological and Communicative Disorders and Stroke, has responded to the need for more effective and less toxic antiepileptic drugs than those currently available. The program screens large numbers of compounds for anticonvulsant activity, conducts toxicology studies, and sponsors clinical trials of promising new drugs for the treatment of epilepsy. This collaboration with the pharmaceutical industry is providing a valuable model for a shared drug development program.
通过在药物研发的关键领域与制药行业合作，国家神经与交流障碍及中风研究所癫痫分支的ADD项目，回应了对比现有药物更有效且毒性更小的抗癫痫药物的需求。该项目筛选大量化合物以检测其抗惊厥活性，进行毒理学研究，并赞助有前景的新型抗癫痫药物的临床试验。这种与制药行业的合作正在为共享药物研发项目提供一个有价值的模式。
